IPCA Laboratories Limited (IN:IPCALAB)
:IPCALAB
Want to see IN:IPCALAB full AI Analyst Report?
Top Page
IPCA Laboratories Limited
(IPCALAB)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹1,666.00
▲(18.68% Upside)
Action:UpgradedDate:11/15/25
IPCA Laboratories earns a score of 73, driven primarily by strong financial performance with robust revenue growth and a solid balance sheet. Bullish technical momentum further supports the score, though an elevated P/E ratio of 43.72 raises valuation concerns, tempering the overall outlook.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion and stability.
Negative Factors
Net Profit Margin Fluctuations
Fluctuating net profit margins can indicate instability in cost management and pricing strategies, affecting long-term profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion and stability.
Read all positive factors
IPCA Laboratories Limited (IPCALAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹389.99B
Dividend Yield0.28%
Average Volume (3M)6.78K
Price to Earnings (P/E)27.6
Beta (1Y)0.25
Revenue Growth8.92%
EPS Growth24.73%
CountryIN
Employees17,335
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)12.20
Shares Outstanding253,659,230
10 Day Avg. Volume6,645
30 Day Avg. Volume6,776
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)5.08
Price to Sales (P/S)3.95
P/FCF Ratio70.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,755.00Price Target Upside25.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)56.86
Revenue Forecast (FY)₹107.53B
IPCA Laboratories Limited Business Overview & Revenue Model
Company Description
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diureti...
How the Company Makes Money
IPCA Laboratories generates revenue primarily through the sale of pharmaceutical formulations and APIs. The company has a strong focus on generic drugs, which are sold at competitive prices to healthcare providers and pharmacies. Key revenue strea...
IPCA Laboratories Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 93.59B | 89.41B | 77.06B | 62.48B | 58.30B | 54.21B |
| Gross Profit | 62.06B | 58.60B | 48.58B | 37.25B | 36.23B | 35.24B |
| EBITDA | 17.61B | 16.67B | 12.64B | 9.46B | 12.75B | 15.07B |
| Net Income | 8.32B | 7.38B | 5.47B | 4.71B | 8.84B | 11.40B |
Balance Sheet | ||||||
| Total Assets | 122.63B | 117.61B | 111.01B | 86.26B | 76.24B | 60.68B |
| Cash, Cash Equivalents and Short-Term Investments | 12.83B | 11.08B | 8.45B | 21.79B | 13.59B | 7.58B |
| Total Debt | 12.79B | 13.63B | 14.38B | 14.81B | 8.07B | 2.65B |
| Total Liabilities | 33.97B | 33.72B | 33.74B | 27.11B | 20.82B | 13.52B |
| Stockholders Equity | 74.27B | 69.48B | 63.32B | 58.42B | 54.92B | 47.02B |
Cash Flow | ||||||
| Free Cash Flow | 3.19B | 5.00B | 5.33B | 3.11B | 3.77B | 7.29B |
| Operating Cash Flow | 7.80B | 12.75B | 9.45B | 8.06B | 8.56B | 10.90B |
| Investing Cash Flow | -2.98B | -8.94B | -12.92B | -7.25B | -8.55B | -5.21B |
| Financing Cash Flow | -2.11B | -2.13B | -5.53B | 5.07B | 4.27B | -3.06B |
IPCA Laboratories Limited Technical Analysis
Neutral
1403.75
Price Trends
1494.28
Negative
1473.21
Negative
1423.15
Positive
Market Momentum
-15.77
Positive
44.26
Neutral
46.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IPCALAB, the sentiment is Neutral. The current price of 1403.75 is below the 20-day moving average (MA) of 1506.29, below the 50-day MA of 1494.28, and below the 200-day MA of 1423.15, indicating a neutral trend. The MACD of -15.77 indicates Positive momentum. The RSI at 44.26 is Neutral, neither overbought nor oversold. The STOCH value of 46.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:IPCALAB.
IPCA Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹389.99B | 27.58 | ― | 0.28% | 8.92% | 24.73% | |
72 Outperform | ₹350.58B | 31.59 | ― | 1.04% | 14.78% | 13.41% | |
66 Neutral | ₹328.80B | 36.01 | ― | 0.86% | 9.47% | 17.05% | |
60 Neutral | ₹189.31B | 119.97 | ― | 0.08% | 2.71% | -40.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹234.12B | 100.15 | ― | ― | 6.13% | ― |
* Healthcare Sector Average
IN:IPCALAB
IPCA Laboratories Limited
1,539.10
148.13
10.65%
IN:AJANTPHARM
Ajanta Pharma Limited
2,754.90
20.50
0.75%
IN:EMCURE
Emcure Pharmaceuticals Limited
1,609.15
600.34
59.51%
IN:JBCHEPHARM
JB Chemicals & Pharmaceuticals Ltd.
2,043.60
473.79
30.18%
IN:NEULANDLAB
Neuland Laboratories Ltd.
14,444.55
2,182.61
17.80%
IN:WOCKPHARMA
Wockhardt Limited
1,417.15
49.90
3.65%
IPCA Laboratories Limited Corporate Events
IPCA Laboratories Expands with New German Subsidiary
Oct 16, 2025
IPCA Laboratories Limited has announced the incorporation of a wholly owned subsidiary, Ipca Pharmaceuticals GmbH, in Germany. This strategic move aims to enhance the company’s operations by holding product registrations and distributing gen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.